<DOC>
	<DOCNO>NCT02522481</DOCNO>
	<brief_summary>The purpose study assess safety efficacy Lumason-enhanced dobutamine stress echo ( DSE ) subject suboptimal leave ventricular endocardial border delineation ( LV EBD ) rest schedule coronary angiography .</brief_summary>
	<brief_title>Evaluation Safety Efficacy Lumason/SonoVue Subjects Undergoing Pharmacologic Stress BR1-141</brief_title>
	<detailed_description>The study design assess safety efficacy Lumason improve visualization LV EBD pharmacologic stress echocardiography examination detection exclusion CAD . The study population consist adult subject refer pharmacological stress echocardiography suboptimal image quality unenhanced ultrasound image rest know suspected CAD . Subjects enrol study representative subject could benefit CEUS stress echocardiography .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Dobutamine</mesh_term>
	<criteria>Provides write Informed Consent willing comply protocol requirement ; Is least 18 year age ; Has suspect know CAD schedule undergo coronary angiography within 6 month LUMASON DSE . Has undergone previous echocardiography prior enrollment ; result suboptimal unenhanced image rest , define ≥ 2 suboptimal adjacent segment apical view . Is pregnant lactate female . Exclude possibility pregnancy : test site institution ( serum urine βHCG ) within 24 hour prior start LUMASON administration ( ) , surgical history ( e.g. , tubal ligation hysterectomy ) , post menopausal minimum 1 year without menses ; Has know hypersensitivity 1 ingredient LUMASON ( sulfur hexafluoride component LUMASON ) ; Has know hypersensitivity dobutamine ; Has ongoing recent ( within last 30 day ) acute myocardial infarction ; Has know righttoleft , bidirectional transient cardiac shunt ( rule agitate saline study perform administration LUMASON ) ; Has electrolyte ( especially potassium magnesium ) abnormality ; Has unstable pulmonary and/or systemic hemodynamic condition e.g . : decompensated inadequately control congestive heart failure ( NYHA Class IV ) ; hypovolemia ; uncontrolled hypertension , i.e . rest systolic blood pressure &gt; 200 mmHg diastolic blood pressure &gt; 110 mmHg ; unstable angina ; acute coronary syndrome ; aortic dissection ; acute pericarditis , myocarditis , endocarditis ; stenosis main leave coronary artery ; hemodynamically significant outflow obstruction leave ventricle , include hypertrophic obstructive cardiomyopathy ; hemodynamically significant cardiac valvular defect ; acute pulmonary embolism ; Has uncontrolled cardiac arrhythmia ; Has significant disturbance conduction ; Has hypertrophic subaortic stenosis ; Has acute illness ( e.g. , infection , hyperthyroidism , severe anemia ) ; Was previously enter study receive investigational compound within 30 day admission study ; Has treat contrast agent either intravascularly orally within 48 hour first LUMASON administration ; Has medical condition circumstance would significantly decrease chance obtain reliable data , achieve study objective , complete study and/or postdose followup examination ; In addition , due use Atropine subject reach targeted heart rate peak dobutamine infusion , subject follow exclude : Glaucoma ; Pyloric stenosis ; Prostatic hypertrophy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Lumason</keyword>
	<keyword>Dobutamine stress echo</keyword>
	<keyword>stress echo</keyword>
	<keyword>coronary artery disease</keyword>
</DOC>